Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer’s Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).
Instructions for Use
Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.
Active Human Recombinant Beta Synuclein Protein Monomer$430.00 – $1,415.00